At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZLAB Zai Lab Ltd
Market Closed 02-06 16:00:00 EST
18.00
+1.02
+6.01%
盘后18.05
+0.05+0.28%
18:49 EST
High18.01Low16.96Vol650.11K
Open17.11D1 Closing16.98Amplitude6.18%
Mkt Cap2.00BTradable Cap1.97BTotal Shares111.00M
T/O11.52MT/O Rate0.59%Tradable Shares109.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Zai Lab price target lowered to $39 from $46 at JPMorgan
TIPRANKS  ·  02-05 21:36
Zai Lab price target lowered to $39 from $46 at JPMorgan
JPMorgan Chase Increases Stake in Zai Lab by Approximately 1.92 Million Shares at HK$13.34 Per Share
Stock News  ·  02-04
JPMorgan Chase Increases Stake in Zai Lab by Approximately 1.92 Million Shares at HK$13.34 Per Share
SPDB Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
TIPRANKS  ·  02-03
SPDB Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
A Look At Zai Lab (NasdaqGM:ZLAB) Valuation As UBS Initiates Coverage And Highlights Global Pipeline Shift
Simply Wall St.  ·  02-02
A Look At Zai Lab (NasdaqGM:ZLAB) Valuation As UBS Initiates Coverage And Highlights Global Pipeline Shift
Zai Lab Ltd (1ZLB) Gets a Buy from Guotai Haitong
TIPRANKS  ·  01-30
Zai Lab Ltd (1ZLB) Gets a Buy from Guotai Haitong
Haitong International Maintains "Outperform" Rating on Zai Lab (09688), Sees Dual Engines Driving Long-Term Global Value
Stock News  ·  01-30
Haitong International Maintains "Outperform" Rating on Zai Lab (09688), Sees Dual Engines Driving Long-Term Global Value
Citi Keeps Their Buy Rating on Zai Lab (ZLAB)
TIPRANKS  ·  01-15
Citi Keeps Their Buy Rating on Zai Lab (ZLAB)
Zhutong Hong Kong Stock Morning Briefing | Ministry of Finance Holds Meeting on Fiscal-Financial Synergy to Boost Domestic Demand; White House Announces 25% Tariff Hike on Specific Semiconductors
Stock News  ·  01-15
Zhutong Hong Kong Stock Morning Briefing | Ministry of Finance Holds Meeting on Fiscal-Financial Synergy to Boost Domestic Demand; White House Announces 25% Tariff Hike on Specific Semiconductors
Zai Lab Rises Over 7% in Morning Session Following Appearance at JPMorgan Healthcare Conference
Deep News  ·  01-14
Zai Lab Rises Over 7% in Morning Session Following Appearance at JPMorgan Healthcare Conference
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
MT Newswires Live  ·  01-13
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
MT Newswires Live  ·  01-12
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
Zai Lab Initiated at Buy by UBS
Dow Jones  ·  01-08
Zai Lab Initiated at Buy by UBS
UBS Initiates Zai Lab at Buy With $35 Price Target
MT Newswires Live  ·  01-07
UBS Initiates Zai Lab at Buy With $35 Price Target
Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Volatility
Simply Wall St.  ·  01-06
Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Volatility
Asian Equities Traded in the US as American Depositary Receipts Climb in Friday Trading
MT Newswires Live  ·  01-02
Asian Equities Traded in the US as American Depositary Receipts Climb in Friday Trading
HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China
Stock News  ·  2025-12-24
HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China
Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration
MT Newswires Live  ·  2025-12-23
Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration
How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial
Simply Wall St.  ·  2025-12-19
How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat
MT Newswires Live  ·  2025-12-12
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals
Simply Wall St.  ·  2025-12-10
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals

Introduction

Company Name.
Zai Lab Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Issue price:
--